ADXS-PSA/Keytruda Combo Prolongs Survival in mCRPC, Early Trial Results Suggest

ADXS-PSA/Keytruda Combo Prolongs Survival in mCRPC, Early Trial Results Suggest
Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda (pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer (mCRPC), and appears to prolong survival compared with standard-of-care therapy, early results from an ongoing Phase 1/2 trial show. The results were announced by Advaxis, the company developing ADXS-PSA, and presented in a poster at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. Its title was “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metas
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *